Drug intelligence / Profile preview

neomycin sulfate + gramicidin + polymyxin b

Development stage
Unknown
Lead developer
Bausch + Lomb
Modality
Peptides, Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Neomycin sulfate + gramicidin + polymyxin b is a prescription **topical ophthalmic combination antibiotic** formulated as a sterile eye-drop solution for superficial bacterial infections of the external eye and its adnexa. The product combines **neomycin**, an aminoglycoside that inhibits bacterial protein synthesis by binding the 30S ribosomal subunit, with **polymyxin B**, a membrane-active polypeptide antibiotic that disrupts the bacterial cell membrane of susceptible organisms, and **gramicidin**, a peptide antibiotic that increases membrane permeability and is particularly active against gram-positive bacteria. It has been marketed under brands including Neosporin Ophthalmic and related trade names, and is used for conditions such as conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis caused by susceptible bacteria.

Brand names
Neosporin OphthalmicNeocidinAK-SporeNeocin PGNeopticOcu-Spore-G
Other names
neomycin and polymyxin b sulfates and gramicidin ophthalmic solutionneomycin sulfate + gramicidin + polymyxin b
02

Targets

30S (Bacterial 30S ribosomal subunit)LPS (Gram-negative bacterial outer membrane lipopolysaccharide)

Beyond the preview

Go deeper on neomycin sulfate + gramicidin + polymyxin b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neomycin sulfate + gramicidin + polymyxin b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call